ExoCoBio key facts
- Developer of regenerative medicine and biopharmaceuticals designed to create value for the healthy life of mankind.
- ExoCoBio’s last known valuation is $510K.
- It has raised $55.3M; the latest was Secondary Transaction - Private ($70K) in Sep 2025.
- Notable investors include SBI Investment, Korea Investment Partners, InterVest, KDB Capital, T.S. Investment — 20 tracked in total.
- Status: Privately Held (backing).
Who backs ExoCoBio
20+- ·The complete investor list: 20 names
- ·Watch ExoCoBio: the Monday email on marks, rounds and moves
ExoCoBio funding rounds
No funding rounds for ExoCoBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
ExoCoBio valuation
ExoCoBio's last known valuation is $510,000. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
ExoCoBio investors
20 investors are on record for ExoCoBio, including SBI Investment, Korea Investment Partners, InterVest and KDB Capital. By type, the record holds 7 venture capital firms and 1 hedge fund.
About ExoCoBio
Developer of regenerative medicine and biopharmaceuticals designed to create value for the healthy life of mankind. The company's products specialize in the development of stem cell-derived exosome therapeutics which are nano-vesicles secreted by cells for intercellular signalings for the growth of skin and hair, enabling clinicians to develop stimulation of cellular tissue regeneration technology alternatives.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2017
- Employees
- 104
- Website
- exocobio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
ExoCoBio’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.